Drugs / 7MW4911
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT07216560 | Jan 2026 → Jul 2027 expected | digestive system cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
| Phase 1/2 | NCT07265622 | Nov 2025 → Jul 2027 expected | cancer | Mabwell (Shanghai) Bioscience Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 7MW4911 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07216560 ↗ |
| Route | Intravenous | “7MW4911 for IV infusion of various dose strengths administered” NCT07265622 ↗ |